• Test Code:
    5441
  • Department:
    Solid Tumors
  • Test Synonyms:
    Solid Tumor Panel Version 3ACVR1AKT1AKT2AKT3ALKAMER1APCAPLNRARARAFARID1AARID2ASF1AATMATRATRXAURKAAXIN1B2MBAP1BARD1BRAFBRCA1BRCA2BRD4BRIP1BUB1BEMSYCASP8CCND1CCND2CCND3CCNE1CD274 (PD-L1)CDH1CDK12CDK4CDK6CDKN1BCDKN2ACHD4CHEK1CHEK2CICCOL2A1CTNNB1DDR2DDX11DDX3XDICER1EGFREGLN1EGLN2EIF1AXEPAS1ERBB2ERBB3ERBB4ERCC2ERCC3ERCC5ESR1FAM175AFANCAFANCCFANCD2FANCEFANCFFANCGFANCMFBXW7FGF19FGF3FGF4FGFR1FGFR2FGFR3FGFR4FHFUBP1GATA3GNA11GNAQGNASH3F3AHIST1H3BHIST1H3CHLA-AHLA-BHLA-CHOXB13HRASIDH1IDH2IDO1IDO2IFNGR1IFNGR2INPP4BIRF1JAK1JAK2KDRKEAP1KIF1BKITKLF4KRASLZTR1MAP2K1 (MEK1)MAP2K2 (MEK2)MAP2K4MAP3K1MAPK1MAXMC1RMDC1MDH2MDM2MDM4MEN1METMLH1MLH3MRE11AMSH2MSH3MSH6MTAPMTORMUTYHMYCMYCNMYOD1NBNNDUFAB1NF1NF2NRASNTRK1NTRK2NTRK3PALB2PBRM1PDCD1LG2PDGFRAPIK3CAPIK3CBPIK3R1PLAG1PLCG1PMS1PMS2POLEPPM1DPPP2R1APPP6CPRKAR1APRKCAPSMB5PTCH1PTENPTPN11PTPRBRAC1RAD50RAD51RAD51BRAD51CRAD51DRAD52RAD54LRAF1RASA1RB1RECQLRETREV7RHEBRICTORRINT1RIT1RNF139RNF43ROS1RPTORRRASSDHASDHAF1SDHAF2SDHAF3SDHAF4SDHBSDHCSDHDSETD2SF3B1SMAD4SMARCA2SMARCA4SMARCB1SMARCE1SMOSOCS1SPENSPOPSTAG2STAT3STK11SUFUTAP1TAP2TAPBPTCEB1TERTTMEM127TP53TP53BP1TRAF7TSC1TSC2VHLXRCC1YAP1YES1
  • CPT Code(s):
    81445
Background:

Features included:

    • Tumor mutation burden estimate (TMB)
    • Identification of microsatellite instability (MSI)
    • Genes related to resistance to immune checkpoint inhibitor treatment (HLA genes, B2M, JAK1, JAK2, IFNGR1, IFGR2)

Screening for clinically informative alterations in oncogenes and tumor suppressor genes is increasingly important in delivering personalized cancer care. The GeneTrails® Comprehensive Solid Tumor Panel is a custom assay that screens for alterations in the 225 genes listed above. These genes were selected on the basis of their relevance to current clinical therapies. Alterations may include single nucleotide substitutions, insertions, deletions, and gains or losses in gene copy number. The panel has a lower limit of detection of ~3% mutant allele.

This panel can be complemented with the GeneTrails Gene Fusion Panel to screen for actionable kinase gene fusions.  

Recommended Use:  The panel is useful for characterizing solid tumors of all types, providing information that can help optimize treatment with targeted therapeutics and immune checkpoint inhibitors, particularly in the setting of advanced disease.

Gene List:

ACVR1

CCND1

ERCC2

HLA-A

MDC1

PDGFRA

RB1

SOCS1

AKT1

CCND2

ERCC3

HLA-B

MDH2

PIK3CA

RECQL

SPEN

AKT2

CCND3

ERCC5

HLA-C

MDM2

PIK3CB

RET

SPOP

AKT3

CCNE1

ESR1

HOXB13

MDM4

PIK3R1

REV7

STAG2

ALK

CD274 (PD-L1)

FAM175A

HRAS

MEN1

PLAG1

RHEB

STAT3

AMER1

CDH1

FANCA

IDH1

MET

PLCG1

RICTOR

STK11

APC

CDK12

FANCC

IDH2

MLH1

PMS1

RINT1

SUFU

APLNR

CDK4

FANCD2

IDO1

MLH3

PMS2

RIT1

TAP1

AR

CDK6

FANCE

IDO2

MRE11A

POLE

RNF139

TAP2

ARAF

CDKN1B

FANCF

IFNGR1

MSH2

PPM1D

RNF43

TAPBP

ARID1A

CDKN2A

FANCG

IFNGR2

MSH3

PPP2R1A

ROS1

TCEB1

ARID2

CHD4

FANCM

INPP4B

MSH6

PPP6C

RPTOR

TERT

ASF1A

CHEK1

FBXW7

IRF1

MTAP

PRKAR1A

RRAS

TMEM127

ATM

CHEK2

FGF19

JAK1

MTOR

PRKCA

SDHA

TP53

ATR

CIC

FGF3

JAK2

MUTYH

PSMB5

SDHAF1

TP53BP1

ATRX

COL2A1

FGF4

KDR

MYC

PTCH1

SDHAF2

TRAF7

AURKA

CTNNB1

FGFR1

KEAP1

MYCN

PTEN

SDHAF3

TSC1

AXIN1

DDR2

FGFR2

KIF1B

MYOD1

PTPN11

SDHAF4

TSC2

B2M

DDX11

FGFR3

KIT

NBN

PTPRB

SDHB

VHL

BAP1

DDX3X

FGFR4

KLF4

NDUFAB1

RAC1

SDHC

XRCC1

BARD1

DICER1

FH

KRAS

NF1

RAD50

SDHD

YAP1

BRAF

EGFR

FUBP1

LZTR1

NF2

RAD51

SETD2

YES1

BRCA1

EGLN1

GATA3

MAP2K1 (MEK1)

NRAS

RAD51B

SF3B1

BRCA2

EGLN2

GNA11

MAP2K2 (MEK2)

NTRK1

RAD51C

SMAD4

BRD4

EIF1AX

GNAQ

MAP2K4

NTRK2

RAD51D

SMARCA2

BRIP1

EPAS1

GNAS

MAP3K1

NTRK3

RAD52

SMARCA4

BUB1B

ERBB2

H3F3A

MAPK1

PALB2

RAD54L

SMARCB1

EMSY

ERBB3

HIST1H3B

MAX

PBRM1

RAF1

SMARCE1

CASP8

ERBB4

HIST1H3C

MC1R

PDCD1LG2

RASA1

SMO

 

Methodology:

The Comprehensive Solid Tumor Panel is performed on DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue using next-generation sequencing on an Illumina NextSeq500.  An amplicon-based library is prepared by amplifying input DNA with customized primers followed by modification with adaptors and molecular bar codes. The primers include unique molecular indices, which allow assessment of library complexity. All specimens are reviewed by a board-certified pathologist prior to testing to ensure that the submitted material is representative of the target tumor, and that there is adequate tumor fraction for testing.

  • Input DNA: 50 ng
  • Minimum read depth per amplicon:   250

Specimen Requirements:

  • A paraffin block or
  • 10 unstained sections  (4-5 micron)
A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information.

Test Performed (Days):

Twice weekly

Turn Around Time:

14 days

Shipment Sensitivity Requirements:

  • Package and ship specimen to remain cold, but not frozen. 
  • Ship via overnight express, using the FedEx priority overnight label provided. 
  • Contact Client Services at (855) 535-1522 for shipping kits and instructions.

References:

Additional Info: